Oncomatryx Biopharma Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 36

Employees

  • Latest Deal Type
  • PE Growth

  • Financing Rounds
  • 14

  • Investments
  • 1

Oncomatryx Biopharma General Information

Description

Developer of stroma-targeted precision drugs and diagnostics intended to fight against invasive tumours. The company is aimed at discovering new mechanisms and proteins in the peritumoral stroma, the cells, and the extracellular matrix that surround the tumour and facilitate its invasiveness, resistance to treatment, and metastasis, enabling doctors to diagnose, prognosis, and fight against tumour invasiveness.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Corporate Office
  • Parque Tecnológico de Bizkaia 801B-2P
  • 48160 Derio
  • Spain
+34 946
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Parque Tecnológico de Bizkaia 801B-2P
  • 48160 Derio
  • Spain
+34 946

Oncomatryx Biopharma Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Oncomatryx Biopharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Oncomatryx Biopharma‘s full profile, request access.

Request a free trial

Oncomatryx Biopharma Patents

Oncomatryx Biopharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4789684-A1 Anti-endoglin antibody-drug conjugates Pending 05-Feb-2025
EP-4789685-A1 Anti-endoglin antibody-drug conjugates Pending 05-Feb-2025
WO-2026167104-A1 Anti-endoglin antibody-drug conjugates Pending 05-Feb-2025
WO-2026167116-A1 Anti-endoglin antibody-drug conjugates Pending 05-Feb-2025
EP-4759329-A1 Combination therapy for the treatment of metastatic cancer Pending 10-Dec-2024 A61K47/6803
To view Oncomatryx Biopharma’s complete patent history, request access »

Oncomatryx Biopharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oncomatryx Biopharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Oncomatryx Biopharma‘s full profile, request access.

Request a free trial

Oncomatryx Biopharma Investments (1)

Oncomatryx Biopharma’s most recent deal was a Buyout/LBO with Tube Pharmaceuticals. The deal was made on 08-Mar-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Tube Pharmaceuticals 08-Mar-2023 Buyout/LBO Biotechnology
To view Oncomatryx Biopharma’s complete investments history, request access »

Oncomatryx Biopharma FAQs

  • When was Oncomatryx Biopharma founded?

    Oncomatryx Biopharma was founded in 2009.

  • Where is Oncomatryx Biopharma headquartered?

    Oncomatryx Biopharma is headquartered in Derio, Spain.

  • What is the size of Oncomatryx Biopharma?

    Oncomatryx Biopharma has 36 total employees.

  • What industry is Oncomatryx Biopharma in?

    Oncomatryx Biopharma’s primary industry is Drug Discovery.

  • Is Oncomatryx Biopharma a private or public company?

    Oncomatryx Biopharma is a Private company.

  • What is Oncomatryx Biopharma’s current revenue?

    The current revenue for Oncomatryx Biopharma is .

  • How much funding has Oncomatryx Biopharma raised over time?

    Oncomatryx Biopharma has raised $146M.

  • Who are Oncomatryx Biopharma’s investors?

    Basque Government, Kutxa Fundazioa, European Innovation Council, INNVIERTE SICC, and Bilbao Bizkaia Kutxa Fundación Bancaria are 5 of 7 investors who have invested in Oncomatryx Biopharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process